Dr. David Deaton serves as a member of TransMed7’s Clinical and Scientific Advisory Board.
Dr. Deaton received a Bachelor of Arts degree in Chemistry from Haverford College and a Medical Doctor degree from Duke University School of Medicine. He completed his Surgical Residency and Research Fellowship at the Hospital of the University of Pennsylvania, and his Vascular Fellowship at UCLA.
Dr. Deaton has practiced in a variety of private and academic settings, most recently as Chief, Division of Vascular and Endovascular Surgery at MedStar Georgetown University Hospital in Washington, DC, and also as Director, Clinical Vascular Research, and Founder and Medical Director, Vascular Non-Invasive Laboratory. He has held academic appointments at UCLA, the University of Pennsylvania, East Carolina University, and the University of Maryland, in addition to his tenure at Georgetown. Dr. Deaton left Georgetown in 2013 to devote the majority of his time to medical device innovation and development. He currently holds a part-time position as a Staff Vascular Surgeon at the Cleveland Clinic Foundation in Cleveland, Ohio.
Dr. Deaton has been involved in the development and evolution of endovascular aortic therapy since 1993. He was a leading investigator in the first U.S. EVAR trial and provided FDA panel testimony for the first approved EVAR device (EVT/Ancure) in the United States in 1999. Dr. Deaton served as a primary investigator in the Phase I clinical trials of four different aortic endograft technologies and performed the first-in-patient and first U.S. cases using the Aptus device.
Dr. Deaton has held leadership positions in several vascular societies, most recently as Chairman of the Political Action Committee of the SVS. His interest in new translational vascular therapies resulted in numerous roles at established and start-up medical device companies over the last 20 years. He has authored both peer and non-peer reviewed articles as well as vascular text chapters throughout his career, and has been a speaker and faculty member at approximately 150 conferences in the U.S. and internationally.